Rankings
▼
Calendar
JAZZ Q3 2024 Earnings — Jazz Pharmaceuticals plc Revenue & Financial Results | Market Cap Arena
JAZZ
Jazz Pharmaceuticals plc
$12B
Q3 2024 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$1.1B
+8.5% YoY
Gross Profit
$943M
89.4% margin
Operating Income
$260M
24.7% margin
Net Income
$215M
20.4% margin
EPS (Diluted)
$3.42
QoQ Revenue Growth
+3.0%
Cash Flow
Operating Cash Flow
$399M
Free Cash Flow
$388M
Stock-Based Comp.
$60M
Balance Sheet
Total Assets
$12.3B
Total Liabilities
$8.1B
Stockholders' Equity
$4.2B
Cash & Equivalents
$2.2B
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$1.1B
$972M
+8.5%
Gross Profit
$943M
$870M
+8.4%
Operating Income
$260M
$172M
+50.9%
Net Income
$215M
$147M
+46.5%
Revenue Segments
Xywav
$388M
37%
Epidiolex/Epidyolex
$252M
24%
Rylaze/Enrylaze
$99M
9%
Zepzelca
$86M
8%
Defitelio/Defibrotide
$66M
6%
High Sodium AG Oxybate Product Royalty Revenue
$58M
6%
Xyrem
$58M
6%
Vyxeos
$34M
3%
Other Royalty And Contract Revenues
$7M
1%
Sativex
$5M
0%
Other Products
$2M
0%
Geographic Segments
UNITED STATES
$954M
90%
Europe
$77M
7%
Other Countries
$24M
2%
← FY 2024
All Quarters
Q4 2024 →